| Literature DB >> 25898125 |
Vinu Krishnan1, Xian Xu, Dakota Kelly, Adam Snook2, Scott A Waldman2, Robert W Mason1, Xinqiao Jia, Ayyappan K Rajasekaran3.
Abstract
Nanomedicine has advanced to clinical trials for adult cancer therapy. However, the field is still in its infancy for treatment of childhood malignancies such as acute lymphoblastic leukemia (ALL). Nanotherapy offers multiple advantages over conventional therapy. It facilitates targeted delivery and enables controlled release of drugs to reduce treatment-related side effects. Here, we demonstrate that doxorubicin (DOX) encapsulated in polymeric nanoparticles (NPs) modified with targeting ligands against CD19 (CD19-DOX-NPs) can be delivered in a CD19-specific manner to leukemic cells. The CD19-DOX-NPs were internalized via receptor-mediated endocytosis and imparted cytotoxicity in a CD19-dependent manner in CD19-positive ALL cells. Leukemic mice treated with CD19-DOX-NPs survived significantly longer and manifested a higher degree of agility, indicating reduced apparent systemic toxicity during treatment compared to mice treated with free DOX. We suggest that targeted delivery of drugs used in childhood cancer treatment should improve therapeutic efficacy and reduce treatment-related side effects in children.Entities:
Keywords: CD19; acute leukemia; doxorubicin; endocytosis; nanoparticles; xenograft model
Mesh：
Substances：
Year: 2015 PMID： 25898125 PMCID： PMC4540184 DOI： 10.1021/acs.molpharmaceut.5b00071
Source DB: PubMed Journal: Mol Pharm ISSN： 1543-8384 Impact factor: 4.939